Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Substituição dos sorotipos causadores da Doença Pneumocócica

Os Drs. Otávio Cintra (CRM-SP 65092) e Renato Kfouri (CRM-SP 59492) comentam sobre o estudo realizado no Reino Unido que aborda as consequências de substituição dos sorotipos causadores da doença e o impacto da introdução da vacina PCV10 no Brasil.

Video player requires JavaScript enabled. You can download this video here: https://edgesuite.gskstatic.com/HealthSites/Health/Brazil/MP4/Portal_Medico/20180614-br-vac-ESPID-meningite-0083-18s.mp4

   

  • Referências

    1. SYNFLORIX [vacina pneumocócica 10-valente (conjugada)]. Bula da vacina.

    2. SARTORI, AL. et al. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS ONE, 12(6): e0179222, 2017.

    3. ANDRADE, AL. et al. Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil. PLoS ONE, 9(6): e98128, 2014.

    4. SGAMBATTI, S. et al. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine 34(5): 663–670, 2016. Epub.

    5. OLIVEIRA, LH. et al. Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review.

    6. BRASIL. Ministério da Saúde. Informe Técnico da vacina pneumocócica 10-valente (conjugada). Disponível em: <http://www.sgc.goias.gov.br/upload/links/arq_723_infotec.pdf>. Acesso em: 13 jun. 2018.

    7. SÁFADI, MAP. et al. A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines. Jornal de Pediatria, 88(3): 195-202, 2012.

    8. OLIVEIRA, LH. et al. Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review. PLoS ONE, 11(12): e0166736, 2016.

    9. ANDRADE, AL. et al. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A  timeseries analysis. PLoS ONE, 12(9): e0184204, 2017.

    10. INTERNATIONAL VACCINE ACCESS CENTER. Pneumococcal Conjugate Vaccine (PCV) Product Assessment. Disponível em: <http://ivac.jhu.edu/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf >. Acesso em: 14 jun. 2018.

    11. LANDHANI, S. et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis, 18: 441-51, 2018.